These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17130275)

  • 1. Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization.
    de Francisco AL; Piñera C; Palomar R; Arias M
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S281-5. PubMed ID: 17130275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Atheroma and vascular calcification in hemodialysis patients].
    Joki N; Tanaka Y
    Clin Calcium; 2010 Jul; 20(7):1061-6. PubMed ID: 20585185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium-sensing receptor as a potential modulator of vascular calcification in chronic kidney disease.
    Caudrillier A; Mentaverri R; Brazier M; Kamel S; Massy ZA
    J Nephrol; 2010; 23(1):17-22. PubMed ID: 20091482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management.
    Toussaint ND; Kerr PG
    Nephrology (Carlton); 2007 Oct; 12(5):500-9. PubMed ID: 17803475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
    Iseki K
    Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
    Goodman WG
    Semin Dial; 2004; 17(3):209-16. PubMed ID: 15144547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Stubbs JR; Wetmore JB
    Semin Dial; 2011; 24(3):298-306. PubMed ID: 21682772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
    Terai K; Nara H; Takakura K; Mizukami K; Sanagi M; Fukushima S; Fujimori A; Itoh H; Okada M
    Br J Pharmacol; 2009 Apr; 156(8):1267-78. PubMed ID: 19302594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
    Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
    Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular calcification in uremic conditions: new insights into pathogenesis.
    Cozzolino M; Gallieni M; Brancaccio D
    Semin Nephrol; 2006 Jan; 26(1):33-7. PubMed ID: 16412823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of hyperphosphatemia ; phosphate-binder].
    Yokoyama K
    Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.